Blue Jet Healthcare: Latest Updates

Q3 FY26 Financial Performance For the quarter ended December 31, 2025 (reported February 13, 2026), Blue Jet Healthcare experienced a significant downturn. Revenue from operations fell by nearly 40% year-on-year to ₹192.41 crore, compared to ₹318.38 crore in the previous year's quarter. This decline was attributed to lower sales volumes in the pharma intermediates, API, and artificial sweetener segments. Profitability and Margins The company's Net Profit plummeted by 59.4% year-on-year to ₹40.17 crore. Profitability was further impacted by margin compression, with the EBITDA margin dropping to 24% from 39% in the year-ago period. On a sequential basis, while revenue grew 16% compared to Q2 FY26, net profit actually declined by 23% due to a sharp 25% surge in total expenses and a one-time inventory write-off. Strategic and Operational Milestone Despite the financial headwind, the company confirmed the completion of land possession near Vizag by executing the final sale deed. Additionally, it has signed a 10-year lease for a new 57,240 sq. ft. R&D center in Hyderabad. These steps are part of a long-term strategy to build additional production capacity and enhance research capabilities in contrast media and advanced intermediates. Credit Ratings and Market Status CARE Ratings recently reaffirmed the company's financial stability by assigning A1+ (Short-term) and A+ (Long-term) ratings to its bank facilities. However, the stock market reacted sharply to the earnings report, with the share price falling approximately 10% on February 13, 2026, to close near its 52-week low of ₹393. Corporate Actions The Board of Directors approved the unaudited results in their meeting on February 13, 2026. No new dividends or stock splits were announced during this meeting. The company continues to operate with a strong promoter holding of approximately 79.8%.